Plus Therapeutics Inc Asset Resilience Ratio
Plus Therapeutics Inc asset resilience ratio. Plus Therapeutics Inc (PSTV) has an Asset Resilience Ratio of 44.34% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PSTV defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Plus Therapeutics Inc (2000–2025)
Asset resilience ratio of Plus Therapeutics Inc from 2000 to 2025. This chart shows how Plus Therapeutics Inc's Asset Resilience Ratio has changed over time. Read PSTV total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Plus Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Plus Therapeutics Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.22 Million | 44.34% |
| Total Liquid Assets | $6.22 Million | 44.34% |
Asset Resilience Insights
- Very High Liquidity: Plus Therapeutics Inc maintains exceptional liquid asset reserves at 44.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Plus Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Plus Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Plus Therapeutics Inc Asset Resilience Ratio by Year (2000–2025)
Plus Therapeutics Inc asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Plus Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.68% | $4.36 Million | $16.32 Million | -26.54pp |
| 2024-12-31 | 53.22% | $3.53 Million | $6.63 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $11.39 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $23.99 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $31.61 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $34.61 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $37.70 Million | -- |
| 2006-12-31 | 15.99% | $3.98 Million | $24.87 Million | -11.84pp |
| 2005-12-31 | 27.83% | $7.84 Million | $28.17 Million | -13.71pp |
| 2004-12-31 | 41.54% | $10.58 Million | $25.47 Million | +0.78pp |
| 2003-12-31 | 40.76% | $11.45 Million | $28.09 Million | -9.79pp |
| 2002-12-31 | 50.55% | $19.88 Million | $39.32 Million | -21.89pp |
| 2001-12-31 | 72.44% | $31.25 Million | $43.14 Million | +1.63pp |
| 2000-12-31 | 70.80% | $37.01 Million | $52.27 Million | -- |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric br… Read more